Trials / Completed
CompletedNCT01508156
Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)
A Phase I/IIa Study Assessing Single and Multiple Doses of HCV NS5A Inhibitor IDX719 in Healthy and HCV-Infected Subjects
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 130 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to test the safety and tolerability of different doses of IDX719 to find the best dose for future studies. The study will also assess the pharmacokinetics of IDX719. No formal hypotheses will be tested.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IDX719 | IDX719 liquid suspension (1 - 100 mg) taken by mouth. |
| DRUG | Placebo | Placebo liquid suspension matching IDX719 taken by mouth. |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2012-07-01
- Completion
- 2012-07-01
- First posted
- 2012-01-11
- Last updated
- 2015-04-27
Source: ClinicalTrials.gov record NCT01508156. Inclusion in this directory is not an endorsement.